1Fareed J, Hoppensteadt DA, Bick RL. An update on heparins at the beginning of the new millennium[J]. Semin Thromb Hemost, 2000, 26(1): 5-21.
2Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanism of action,pharmarcokinetics, dosing, monitoring, efficacy, and safty[J]. Chest, 2001, 119: 64S-94S.
3Hish J, Raschke R. Heparin and low-molecular-weight[J].Chest, 2004, 126: 188S-203S.
4Fareed J, Fu KD, Yang LH, et al. Pharmacokinetics of low molecular weight heparins in animal models[J]. Semin Thromb Hemost, 1999, 25(3): 51-55.
5Alban S, Gastpar R. Plasma levels of total and free tissue factor pathway inhibitor(TFPI) as individual pharmacological parameters of various heparins[J]. Thromb Haemost, 2001, 85: 824-829.
6Smorenburg SM, van Noorden CJF. The complex effects of heparin on cancer progression and metastasis in experimental studies[J]. Pharmacol Rev, 2001, 53: 93-105.
7Falanga A. Biological and clinical aspects of anticancer effects of antithrombotics[J]. Pathophysiol Haemost Thromb, 2003/2004,33(5-6): 389-392.
8Perez-Requejo JL, Lucena-Solano O, Perez-Garcia M, et al. Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin(enoxaparin) [J]. Thromb Res, 1997, 85: 259-265.
9Harenberg J, Malsch R, Angelescu M, et al. Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin[J]. Blood Coag Fibrinol, 1996, 7: 477-483.
10Frampton JE, Faulds D. Parnaparin: a review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders[J]. Drugs, 1994, 47, 652-676.
